Therapeutic Delivery to Central Nervous System.
Therapies for glioblastoma face several physiologic hurdles. The blood-brain barrier (BBB) and blood-brain-tumor barrier (BTB) present impediments to therapeutic delivery of drugs to the central nervous system. Strategies to disrupt or bypass the native BBB are necessary to deliver therapeutic agents. Techniques to bypass the BBB/BTB include implantable controlled-release polymer systems, intracavitary drug delivery, direct injection of viral vectors, and infusion via convection-enhanced delivery. Ideal methods and agents to accomplish the goal providing survival benefit are yet to be determined. Further development of methods to break down or bypass the BBB and BTB is necessary for patients with glioblastoma.
['Kunigelis|Katherine E|KE|', 'Vogelbaum|Michael A|MA|']
D000970:Antineoplastic Agents D001812:Blood-Brain Barrier D001932:Brain Neoplasms D002490:Central Nervous System D016503:Drug Delivery Systems D005909:Glioblastoma D006801:Humans
Glioblastoma Blood-brain barrier Blood-brain-tumor barrier Convection-enhanced delivery Clinical trials